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Abstract
Background: The complement system has been suggested to affect injury or disease of the central
nervous system (CNS) by regulating numerous physiological events and pathways. The activation of
complement following traumatic CNS injury can also result in the formation and deposition of C5b-9
membrane attack complex (C5b-9/MAC), causing cell lysis or sublytic effects on vital CNS cells. Although
complement proteins derived from serum/blood-brain barrier breakdown can contribute to injury or
disease, infiltrating immune cells may represent an important local source of complement after injury. As
the first immune cells to infiltrate the CNS within hours post-injury, polymorphonuclear leukocytes
(PMNs) may affect injury through mechanisms associated with complement-mediated events. However,
the expression/association of both early and terminal complement proteins by PMNs has not been fully
characterized in vitro, and has not observed previously in vivo after traumatic spinal cord injury (SCI).
Method: We investigated the expression of complement mRNAs using rt-PCR and the presence of
complement proteins associated with PMNs using immunofluroescence and quantitative flow cytometry.
Results: Stimulated or unstimulated PMNs expressed mRNAs encoding for C1q, C3, and C4, but not C5,
C6, C7 or C9 in culture. Complement protein C1q or C3 was also detected in less than 30% of cultured
PMNs. In contrast, over 70% of PMNs that infiltrated the injured spinal cord were associated with C1q,
C3, C7 and C5b-9/MAC 3 days post-SCI. The localization/association of C7 or C5b-9/MAC with infiltrating
PMNs in the injured spinal cord suggests the incorporation or internalization of C7 or C5b-9/MAC bound
cellular debris by infiltrating PMNs because C7 and C5b-9/MAC were mostly localized to granular vesicles
within PMNs at the spinal cord epicenter region. Furthermore, PMN presence in the injured spinal cord
was observed for many weeks post-SCI, suggesting that this infiltrating cell population could chronically
affect complement-mediated events and SCI pathogenesis after trauma.
Conclusion: Data presented here provide the first characterization of early and terminal complement
proteins associated with PMNs in vitro and in vivo after SCI. Data also suggest a role for PMNs in the local
internalization or deliverance of complement and complement activation in the post-SCI environment.
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Background
The complement cascade includes at least 30 soluble and
cell membrane bound proteins and has an important role
in the modulation of inflammation and defense against
infection. However, numerous complement proteins have
been suggested to affect central nervous system (CNS)
injury or disease by promoting inflammation, phagoctyo-
sis, and cell lysis [1,2]. Additionally, the activation of
complement via the classical or the alternative pathway
results in the formation and deposition of C5b-9 mem-
brane attack complex (C5b-9/MAC), consisting of com-
plement proteins C5, C6, C7, C8, and C9, which can
promote cell lysis or exert sublytic effects on target cells
[3,4]. Although several studies have demonstrated the
deposition of C5b-9/MAC on neurons and oligodendro-
cytes after traumatic CNS injury [5-7], the contributing
source of complement proteins and activation at the local
environment of trauma has not been clearly defined.
Proteins of the complement system are thought to origi-
nate mostly from the liver; however, previous studies have
reported the expression or production of some comple-
ment proteins by other cell types from the CNS [8,9] and
the immune system [10,11]. Although complement
derived from numerous cell types could contribute to
injury or disease in the CNS, infiltrating immune cells
may represent an important local source of complement
after injury. PMNs are the first peripheral immune cells to
respond to CNS injury, infiltrating within hours. As such,
PMNs have been suggested to promote injury after CNS
trauma [12,13] and have been shown to promote neuro-
toxicity through mechanisms associated with matrix met-
alloproteinases (MMPs), reactive oxygen species (ROS),
and tumuor necrosis factor α (TNF-α) [14]. Although
PMNs are not known to affect injury or neurotoxicity
through complement-mediated events or activation, a few
studies have shown the expression or production of C3
and factor B by cultured PMNs in vitro [15-17]. In addi-
tion, several studies have suggested that exposure of cul-
tured PMNs to biological or pharmacological stimulation
induces the release of several critical terminal proteins (C6
and C7) in PMN cultures [18,19]; however, the expression
of mRNAs encoding for C6 or C7 by PMNs has not been
confirmed. Nevertheless, it has been reported that in some
cases terminal complement proteins are synthesized by
non-resident cell types at sites of inflammation. For exam-
ple, a previous study has suggested that although hepato-
cytes synthesize the majority of proteins of the
complement system, most C7 proteins generated after
liver transplantation are synthesized by other cell types
[20], suggesting a local delivery of complement proteins
and the contribution of complement-mediated events by
a non-hepatocytic cellular source at the site of inflamma-
tion.
Based on the data from previous studies, the potential of
PMNs to deliver complement proteins locally and affect
complement-mediated events or C5b-9/MAC formation
has been suspected but has not been previously character-
ized fully in vitro or investigated in vivo after CNS injury.
A better understanding of the association of PMNs with
complement proteins may have critical implications for
the potential role of PMNs in complement-mediated
events or activation after CNS injury. The data presented
below provide for the first time, a more complete charac-
terization of early and terminal complement proteins
associated with PMNs in vitro and in vivo after traumatic
spinal cord injury (SCI).
Methods
Isolation of PMNs from rat peritoneal cavity
As described previously [21], adult female rats (Sprague
Dawley) received an intraperitoneal injection of sterile
12% sodium caseinate solution and were sacrificed by iso-
flurane inhalation 16 hours later. The peritoneal exudate
containing leukocytes was collected and red blood cells
were lysed with 0.85% ammonium chloride, resuspended
in Hanks' balanced salt solution (HBSS), overlaid on His-
topaque 1077 (Sigma), and then centrifuged at 400 G for
45 minutes at 4°C. PMNs were pelleted and separated
from other leukocytes, which partitioned at the HBSS-His-
topaque interface. PMNs collected were cultured in condi-
tions described below and identified by immunoflu-
orescence and flow cytometry.
Hydrogen peroxide production in PMN culture
Hydrogen peroxide was measured by a one-step assay that
uses 10-acetyl-3,7-dihydroxyphenoxazine (Amplex Red
reagent, Molecular Probes) to detect hydrogen peroxide
concentration in PMN (5.0 × 106/ml HBSS) culture. In the
presence of horseradish peroxidase (HRP), Amplex Red
reagent reacts with hydrogen peroxide to form a fluores-
cent product, resorufin, readable at 560 nm. Briefly and
according a previous study [22], a volume of 100 μl reac-
tion mixture containing 50 μM Amplex Red reagent and
0.1 U/ml HRP in Krebs-Ringer phosphate was mixed with
a volume of 20 μl of Krebs-Ringer containing 1.5 × 104
PMNs, incubated at 37°C for 30 minutes, and was read at
560 nm with a fluorescence microplate reader equipped
for excitation in the range of 530–560 nm and emission
detection at ~590 nm.
Expression of complement mRNAs by cultured PMNs
Expression of C1q, C3, C4, C5, C6, C7, C9, CD59, Crry,
and GADPH mRNAs in cultured PMNs was assayed by rt-
PCR. Briefly, mRNAs were isolated from rat peritoneal
PMNs (5 × 106/ml) after 24 hours in culture with no stim-
ulant or with 0.64 μM phorbol myristate acetate (PMA,
Sigma), TNF-α (2000 U/ml, Serotec), IFN-γ (2000 U/ml,
Serotec), or a combination of TNF-α and IFN-γ. mRNAsJournal of Neuroinflammation 2008, 5:26 http://www.jneuroinflammation.com/content/5/1/26
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isolated from rat liver cells were used as positive controls
for all complement proteins and inhibitors, while nega-
tive controls were absent of mRNAs. mRNAs from PMNs
or liver cells were isolated according to the RNeasy Mini
Kit (Qiagen), and rt-PCR screening conditions and rea-
gents were according to the OneStep RT-PCR Kit (Qia-
gen). For each rt-PCR reaction, 0.25 μg of mRNAs was
used in thermal cycler conditions of 30 minutes at 50°C;
15 minutes at 95°C; followed by 30-repeated cycles of 1
min at 95°C, 1 min at 55°C, 1 min at 72°C; and ended
with 10 minutes at 72°C. Primers used for rt-PCR are
listed in Table 1 and are according to previous studies [23-
26].
Traumatic injury to rat spinal cord
All rats (Sprague Dawley, adult female, 200 grams) were
anesthetized with ketamine/xylazine (100/10 mg/kg i.p.)
before receiving a moderate contusion injury (200 kilo-
dynes) at T9, using an Infinite Horizons Impactor at the
UC Irvine SCI Core Facility. All surgeries were done by
personnel previously trained to perform consistent lami-
nectomies and injuries. Gel foam was placed over the
exposed spinal cord before suturing the muscle and clos-
ing the skin with wound clips. Post-operative animal care
consisted of buprenorphine (50 mg/kg s.c.) twice daily for
2 days, lactated ringers (50 ml/kg s.c.) once daily for 5
days, Baytril (2.5 mg/kg, s.c.) once daily for 14 days, and
manual bladder expression twice daily until animals were
sacrificed at various time points within 42 days post-SCI.
Spinal cord injured rats (n = 5 animals per group) were
anesthetized with a lethal dose of sodium pentobarbital
(0.4 ml) 30 minutes, 2 hours, 24 hours, 3 days, 7 days or
42 days-post SCI, while uninjured control rats received no
injury to the spinal cord. Cord segments (T8-T10) con-
taining the injury epicenter at T9 were then removed from
all animals for immunolabeling or flow cytometric analy-
sis. All work was done with the approval of the Institu-
tional Animal Care and Use Committee at the University
of California, Irvine.
Immunolabeling
Cultured peritoneal PMNs (106/ml) were adhered to
microscope slides by centrifugation (Cytospin, Shandon,
USA), and then fixed with acetone for 10 minutes before
immunolabeled for PMN, C1q, C3, C7, or C5b-9/MAC.
Briefly, cells adhered on slides were quenched in 0.3%
hydrogen peroxide solution for 15 minutes and then incu-
bated in blocking buffer (3% BSA and 0.05% Tween-20)
for 30 minutes. Following several washes with PBS, cells
were incubated in rabbit anti-rat PMN-FITC (1:500, Accu-
rate Chemical) and goat anti-human C1q (1:500,
Advanced Research Technologies (ART)), C3 (1:500,
ART), murine anti-human C7 (1:500, Quidel) or C5b-9/
MAC (1:500, Quidel) solution for 2 hours at room tem-
perature. Immunoreactive complement proteins were
identified using a donkey anti-goat or goat anti-mouse
IgG conjugated with Alexa Fluor 555 (1:1000, Invitro-
gen). All cells were also identified using a nucleic-fluores-
cent dye, Hoechst 33342 (1:1000, Invitrogen). Antibody
control slides were processed identically, except that incu-
bation with primary antibody was eliminated.
Spinal cord segments containing the injury epicenter were
dissected by T8-T10 spinal roots, sunk in 20% sucrose and
4% paraformaldehyde overnight at 4°C, frozen in isopen-
tane at -56°C and then stored at -80°C. Cross sections (30
μm) of spinal cord tissue were cut on a sliding microtone.
Serial sections were collected in PBS with sodium azide
(0.02%) and stored at 4°C until use. Immunohistochem-
istry was performed as previously described with minor
modifications [27]. Briefly, sections are washed with Tris
(100 mM Tris-HCL, pH 7.4) and immediately exposed to
3% hydrogen peroxide and 10% methanol to inactivate
endogenous peroxidases. The sections were then washed
with Tris, then TBS-A (Tris pH 7.4 with 0.4% Triton ×) and
blocked with TBS-B* (Tris + 2% BSA + 2% Donkey
serum). Subsequently, the tissue sections were incubated
with mouse anti-rat CD43 (1:1000, Serotec) in TBS-B* for
2 hours at room temperature, while antibody control sec-
tions were incubated in the absence of primary antibody.
Sections were then washed with TBS-A to remove
Table 1: Sequences of primers used for rt-PCR
Forward (5' to 3') Reverse (5' to 3') Reference or Accession Number
C1q CGACTATGCCCAAAACACCT GGAAAAGCAGAAAGCCAGTG Fan et al. 2004
C3 GACCTGCGACTGCCCTACTCT CTGATGAAGTGGTTGAAGACG X52477
C4 AGACCCGCAACTTTCTGGTCC TGAGCTCAGGGATCCAGAGTC U42719
C5 GACCTGCAGCTCCTGCATCAGA CCTTCCCAACAGCATGCCTTTGT X91892
C6 GGGGCAAGTATGACCTTCTC TGGGGACCGTTTTTCACAGT Qian et al. 1999
C7 CAGAATTCTGTCCATCACCTC GAATTCTGCAG1TFCTCCCAG Oka et al. 2001
C9 TAATGGTGACAACGACTGTGG TGACAAGTAGGATGACAATCG U52948
CD59 ATGCTACAACTGTTTAGACCC CTTCGAAGCTTTTGTTACACAAGT U48225
Crry GTTCTTGATGGAGTGGAAAGC CTGAGGCTGAACACAGCTGTC Sohn et al. 2000
GADPH TGAAGGTCGGTGTCAACGGATTTGGC CATGTAGGCCATGAGGTCCACCAC Sohn et al. 2000Journal of Neuroinflammation 2008, 5:26 http://www.jneuroinflammation.com/content/5/1/26
Page 4 of 13
(page number not for citation purposes)
unbound antibody. Following the washes, the tissue sec-
tions were blocked with TBS-B* and then incubated in the
appropriate biotinylated donkey secondary antibody
(1:500, Jackson) in TBS-B* for 1 hour at room tempera-
ture. Sections were then washed with TBS-A to remove any
unbound secondary antibody and then incubated in ABC
reagent (Vector laboratories methodology) for 1 hour at
room temperature. Following ABC exposure, the tissue
sections were washed first with TBS-A, followed by two
washes with Tris and then exposed to diaminobenzidine
(DAB; Vector Laboratories) solution for 4 minutes to vis-
ualize formation of brown precipitate.
Tissue sections used for confocal imaging were prepared
as described above and were incubated in rabbit anti-rat
PMN-FITC (1:500, Accurate Chemical) and murine anti-
human C7 (1:500, Quidel) or C5b-9/MAC (1:500,
Quidel) in TBS-B* for 2 hours at room temperature. Fol-
lowing several washes, immunoreactive complement pro-
teins were identified using goat anti-mouse IgG
conjugated with Alexa Fluor 555 (1:1000, Invitrogen) in
TBS-B* for 1 hour at room temperature. All cells were also
identified using a nucleic-fluorescent dye, Hoechst 33342
(1:1000, Invitrogen). Confocal imaging was conducted
using a Bio-Rad Radiance 2000 system and LASERSHARP
2000 software with lambda strobing to reduce bleed-
through associated with simultaneous scanning.
Flow cytometry
Spinal cord tissues (T8-T10) from five animals per group
were dissociated in trypsin (0.5 mg/ml) and collagenase
(1 mg/ml), and debris was separated from cells by centrif-
ugation of cell suspension overlayed on OptiPrep gradient
(Fisher) as described in previous studies [28,29]. Col-
lected spinal cord cells or PMNs isolated from rat perito-
neal cavity were incubated 5 minutes in 0.1% Triton ×-
100 solution; 30 minutes in 100% normal rabbit, goat, or
murine serum; 1 hour with rabbit anti-rat PMN-FITC
(1:500; Accurate Chemical) and goat anti-human C1q
(1:500, Advanced Research Technologies (ART)), C3
(1:500, ART), murine anti-human C7 (1:500, Quidel) or
C5b-9/MAC (1:500, Quidel) diluted in HBSS; 1 hour with
chicken anti-goat or rabbit anti-mouse Cy5 conjugated
IgGs (1:500, Invitrogen) diluted in HBSS; and 30 minutes
with propidium iodide (1:100; Molecular Probes) to label
dead cells before analyzed on a FASC Calibur (Becton-
Dickinson) flow cytometer. Cell viability was typically
more than 90% and all flow cytometric gates were set
using control IgG isotype labeled cells or spinal cord cells
from uninjured animals. The mean values of cells positive
for PMN, C1q, C3, C7, or C5b-9/MAC as determined by
flow cytometry were expressed as percent (± s.e.) relative
to control IgG isotype labeled cells or spinal cord cells
from uninjured animals.
Statistical analysis
All experimental groups were compared with their respec-
tive controls using unpaired Student's t tests. Statistical
significance was defined at P < 0.05.
Results
Cultured PMNs express mRNAs of early complement but 
not terminal complement associated with C5b-9/MAC 
formation in vitro
Although previous studies have shown that cultured
PMNs express mRNAs encoding for C3 and Factor B, it is
not clear from these studies whether PMNs express other
early complement proteins or terminal proteins necessary
for C5b-9/MAC formation. The following experiments
investigate whether cultured PMNs or PMNs stimulated
with PMA, TNF-α, or IFN-γ express a complete spectrum
of complement mRNAs, which may have important
implications for a potential role of PMNs in complement-
mediated events or the formation of C5b-9/MAC after
SCI.
PMNs isolated from rat peritoneal cavity were confirmed
to have 96% purity by immunofluorescence and flow
cytometry (Figure 1). After 24 hours in culture with or
without stimulation by PMA (0.64 μM), TNF-α (2000 U/
ml), IFN-γ (2000 U/ml) or TNF-α + IFN-γ, PMNs were
lysed and total RNAs collected for assay of mRNA expres-
sion of complement using rt-PCR. Activation of PMNs
with stimulants was confirmed by the release of reactive
oxygen species (hydrogen peroxide) in PMN cultures (Fig-
ure 2). PMA is a synthetic stimulant that diffuses into the
cytoplasm of PMNs and activates protein kinase C (PKC)
resulting in the subsequent generation of hydrogen perox-
ide. In contrast, cytokines such as TNF-α and IFN-γ bind
specifically to receptors on PMNs, resulting in an
increased uptake of calcium and the production of hydro-
gen peroxide by PMNs. The different mechanisms by
which PMA and cytokines activate PMNs produced differ-
ent levels of hydrogen peroxide in PMN culture, demon-
strating that PMNs stimulated with PMA generated higher
levels of hydrogen peroxide than those stimulated with
TNF-α or IFN-γ by approximately two-fold (Figure 2).
As shown in Figure 3 by rt-PCR, both unstimulated PMNs
and stimulated PMNs expressed mRNAs encoding for
C1q, C3, and C4, but not C6, C7, and C9 in culture. The
faint C5 signal observed could have been due to either
background noise or very low C5 expression by PMNs. In
contrast, mRNAs of all complement proteins tested were
detected in total RNA harvested from rat liver. As dis-
cussed above for hydrogen peroxide production, different
activation mechanisms by PMA and cytokines may also
account for the difference in C3 expression observed in
this experiment, because in contrast to TNF-α or IFN-γJournal of Neuroinflammation 2008, 5:26 http://www.jneuroinflammation.com/content/5/1/26
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activation, PMA activation decreased C3 mRNA expres-
sion by PMNs (Figure 3).
Besides the early complement mRNAs, cultured PMNs
also expressed mRNAs encoding for CD59 and Crry,
which are inhibitors of complement-mediated lysis. As
discussed above for C3, mRNA expression of these com-
plement inhibitors by PMNs was also decreased by PMA
activation, suggesting that PKC activity enhancement in
response to PMA stimulation inhibits PMN expression of
CD59 and Crry, and therefore, may contribute to the short
lifespan of several days for PMNs. However, previous
studies have shown that PMA and PKC activity enhanced
CD59 expression in cancer cells and therefore, increased
the survival of these cells [30,31]. The contrasting PMA-
induced CD59 expression in PMNs and cancer cells sug-
gests different responses by these cell types to PMA stimu-
lation. Furthermore, PMN expression of mRNAs encoding
for these complement inhibitors in several other states of
activity affirms the detection of membrane-bound CD59
and Crry proteins on PMN surfaces as demonstrated in
previous studies [32,33], supporting a self-protective role
for these PMN-generated inhibitors of complement-medi-
ated lysis under certain stimulating conditions. However,
it is feasible that these PMN-generated inhibitors of com-
plement-mediated lysis may also take part in the complex
regulation of complement activation and function in the
local injury environment.
Cultured PMNs are associated with early complement 
proteins but not C5b-9/MAC in vitro
We have shown above that cultured PMNs express some
complement mRNAs, we next ascertained whether these
specific mRNAs are translated into proteins. Immunoflu-
orescence of rat peritoneal PMNs using fluorescent anti-
bodies for PMNs and C1q, C3, or C5b-9/MAC
demonstrated that some, but not all cultured PMNs were
associated with C1q and C3 proteins; however, as
expected from the rt-PCR data above, cultured PMNs were
negative for C5b-9/MAC immunofluorescent labeling
(Figure 4). The association of complement proteins with
cultured PMNs was also confirmed by flow cytometry
(Figure 5). Cultured PMNs double-labeled with both a
FITC-conjugated anti-PMN antibody and a Cy5-conju-
gated antibody for C1q, C3, or C5b-9/MAC, or appropri-
ate IgG controls showed that nearly all cells were PMNs
(as shown in Figure 1), and that 30.1% and 24.1% of cul-
tured PMNs were associated with C1q (Figure 5B &5E)
and C3 (Figure 5C &5E) respectively. In contrast, PMNs
were negative for C5b-9/MAC (Figure 5D &5E), confirm-
Rat peritoneal PMNs were activated by PMA, TNF-α, or  IFN-γ to release hydrogen peroxide Figure 2
Rat peritoneal PMNs were activated by PMA, TNF-α, 
or IFN-γ to release hydrogen peroxide. PMNs (5.0 × 
106/ml) cultured with or without PMA (0.64 μM), TNF-α 
(2000 U/ml), or IFN-γ (2000 U/ml) stimulation released high 
levels of hydrogen peroxide. # = significantly different (P < 
0.05) from PMN only. n = 6. Number of experiment replica-
tion = 3.
Rat peritoneal neutrophils (PMNs) were identified by immunofluorescence (A, labeled with Hoechst (blue) and an anti-PMN  anti-body (green)) and flow cytometry (C) Figure 1
Rat peritoneal neutrophils (PMNs) were identified by immunofluorescence (A, labeled with Hoechst (blue) and 
an anti-PMN anti-body (green)) and flow cytometry (C). All flow cytometric gates were set using control IgG isotype 
labeled cells (B). Over 95% of cells isolated were PMNs; scale bar = 10 μm.Journal of Neuroinflammation 2008, 5:26 http://www.jneuroinflammation.com/content/5/1/26
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ing the rt-PCR data above that showed a lack of mRNAs
encoding for terminal complement proteins in cultured
PMNs (Figure 3).
PMN infiltration into the injured spinal cord peaks 24 
hours and persists after acute traumatic SCI
Although complement-mediated events and lysis are gen-
erally thought to be part of a systemic response driven by
the liver, there is increasing evidence suggesting that com-
plement-mediated events/lysis are also driven locally by
immune cells infiltrating sites of injury. As a principal
immune cell to infiltrate the spinal cord after injury,
PMNs may be an important source of complement. How-
ever, PMNs have not been shown previously to be associ-
ated with complement proteins in the injured spinal cord
after SCI.
The time course of PMN infiltration in rat spinal cord tis-
sue after SCI was investigated using flow cytometry to
quantitate the number of PMNs in the spinal cord with
respect to other CNS and infiltrating cells in the cord. Spi-
nal cord epicenter tissues (segment T8-T10) collected
from uninjured controls and spinal cord injured animals
2 hours, 24 hours, 3 days, or 7 days after SCI were disso-
ciated and labeled with a FITC-conjugated PMN antibody,
before cells were analyzed on a FACS Calibur flow cytom-
eter (Figure 6A). With respect to uninjured control, PMNs
were detected in the injured spinal cord beginning 2 hours
(0.9% ± 0.3) post-injury and peaked 24 hours post-injury,
at which time 5.5% ± 0.4 were PMNs (Figure 6B). At 3
days and 7 days post-SCI, PMN number decreased to
2.4% ± 0.3 and 1.4% ± 0.3 of total cells in the cord (T8-
T10) respectively. Although previous studies have sug-
gested that PMN infiltration is an acute event after SCI,
PMN number could be detected in the spinal cord 6
months post-SCI, at approximately 3% of total cells as
determined by flow cytometry (data not shown). Simi-
larly and as shown by immunohistochemistry, there are
elevated numbers of PMNs at the injury epicenter region
of the cord 3 days post-SCI (Figure 7A) and smaller num-
bers of PMNs remain detectable 42 days post-SCI (Figure
7B), as quantified by flow cytometry and stereological
quantitative assessment (data not shown). Together with
in vitro data presented above showing the association of
PMNs with some early complement proteins, the elevated
PMN numbers at the injury epicenter region suggest that
PMNs could contribute to increased complement-medi-
ated events/lysis at the local injury environment.
Infiltrating PMNs are associated with early complement 
proteins in vivo after traumatic SCI
Although the data presented above show that cultured
PMNs were associated with the early complement pro-
teins in vitro, the association/co-localization of comple-
ment proteins with PMNs that have infiltrating into the
injured spinal cord has not been previously characterized.
The association of complement proteins with infiltrating
PMNs was tested for the first time in vivo by flow cytom-
etry, in which dissociated cells from injured spinal cord
Rat peritoneal PMNs express early proteins (C1q, C3, and  C4) but not terminal proteins (C5, C6, C7, and C9) of the  complement system, shown by rt-PCR Figure 3
Rat peritoneal PMNs express early proteins (C1q, 
C3, and C4) but not terminal proteins (C5, C6, C7, 
and C9) of the complement system, shown by rt-
PCR. mRNAs were collected from rat peritoneal PMNs (5 × 
106/ml) after 24 hours in culture with no stimulant or with 
PMA (0.64 μM), TNF-α (2000 U/ml), IFN-γ (2000 U/ml), or a 
combination of TNF-α and IFN-γ. Positive control mRNAs 
for all complement proteins and inhibitors (CD59 and Crry) 
of complement activation were isolated from rat liver, while 
negative controls were absent of mRNAs.Journal of Neuroinflammation 2008, 5:26 http://www.jneuroinflammation.com/content/5/1/26
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tissues were analyzed for PMN and complement markers
(Figure 8). Most complement proteins detected immedi-
ately within 1 day post-SCI could likely originate from the
serum as a result of the blood-spinal-barrier disruption;
therefore, spinal cord tissues of rats 3 days post-SCI were
used accordingly. Cells dissociated from spinal cord tissue
(T8-T10) of uninjured controls (Figure 8A) or spinal cord
injured rats (Figure 8B &8C) were labeled with a FITC-
conjugated anti-PMN antibody and a Cy5-conjugated
antibody for C1q, C3, C7 or C5b-9/MAC, or appropriate
IgG controls before analyzed on a flow cytometer.
Three days following SCI (Figure 8B), the number of cells
at the injury epicenter region (T8-T10) that were positive
for early complement proteins (C1q or C3) in the spinal
cord increased to 5.6% and 6.3% respectively, compared
to 1.3% and 1.4% from uninjured controls (Figure 8A).
However, more than 30% of total cells positive for C1q or
C3 in the spinal cord epicenter were identified as PMNs
(Figure 8C &8E). Therefore, while other cells besides
PMNs were associated with C1q or C3 in the cord 3 days
post-SCI, the infiltrating PMNs represented a significant
fraction of this labeling. Additionally, of all the PMNs that
infiltrating the spinal cord epicenter region, most (over
70%) were also positive for C1q or C3 (Figure 8C &8D).
In contrast with the in vitro data above that showed less
than 30% of cultured PMNs were associated with C1q or
C3 proteins (Figure 5), data presented here show that after
3 days following SCI, 78% or 70% of infiltrating PMNs
exhibited C1q or C3 respectively, suggesting an elevated
number of infiltrating PMNs synthesizing or internalizing
complement proteins in the injured spinal cord. These in
vivo data support the in vitro data that show the associa-
tion of cultured PMNs with most early complement pro-
Rat peritoneal PMNs are associated with the early proteins of the complement system but not C5b-9/MAC in vitro, shown by  flow cytometry Figure 5
Rat peritoneal PMNs are associated with the early proteins of the complement system but not C5b-9/MAC in 
vitro, shown by flow cytometry. Cells (5 × 106/ml) labeled with a FITC-conjugated anti-PMN antibody and a Cy5-conju-
gated antibody for C1q (B), C3 (C), or C5b-9 (D), or appropriate IgG controls (A) showed that nearly all cells were PMNs (B, 
C, & D), but only some cells were associated with C1q (B & E) and C3 (C & E); however, these cells were not associated with 
C5b-9/MAC (D & E). All flow cytometric gates were set using control IgG isotype labeled cells. # = significantly differ from IgG 
control. n = 3. Number of experiment replication = 3.
Rat peritoneal PMNs are associated with the early proteins of the complement system but not C5b-9/MAC in vitro, shown by  immunofluorescence Figure 4
Rat peritoneal PMNs are associated with the early proteins of the complement system but not C5b-9/MAC in 
vitro, shown by immunofluorescence. PMNs were labeled with an anti-PMN anti-body (green) and an anti-C1q (A), anti-
C3 (B), or anti-C5b-9/MAC (C) antibody (red). Scale bar = 10 μm.Journal of Neuroinflammation 2008, 5:26 http://www.jneuroinflammation.com/content/5/1/26
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teins, providing important implications for a PMN role in
the local deliverance of complement, contributing to the
elevated complement levels and complement-mediated
events in the injured spinal cord.
Infiltrating PMNs are associated with the terminal 
complement proteins in vivo after traumatic SCI
In contrast to the data above that showed a lack of termi-
nal complement expression by cultured peritoneal PMNs,
the characterization of the injured spinal cord region of
rats 3 days post-SCI show that most infiltrating PMNs
were associated with labeling for C7 and C5b-9/MAC. As
shown in Figure 8B, the number of cells positive for C7 or
C5b-9/MAC in the spinal cord epicenter region increased
to 8.9% or 8.2% respectively (Figure 8B), while 30% of
total cells positive for C7 or C5b-9/MAC in the spinal cord
were PMNs (Figure 8C &8E). A different analysis of the
data (shown in Figure 8D) also clarified that although
most infiltrating PMNs (more than 95%) were associated
with C7 or C5b-9/MAC (Figure 8C &8D), other cell types
were also positively labeled for these terminal comple-
ment proteins.
The association of C7 or C5b-9/MAC with infiltrating
PMNs at the injury epicenter region was also confirmed by
immunofluorescent confocal imaging of spinal cord cross
sections 3 days post-SCI (Figure 9), demonstrating the co-
localization of terminal complement proteins with PMNs.
In most PMNs, terminal complement C7 (Figure 9A) and
C5b-9/MAC (Figure 9B) appears to be localized in granu-
lar vesicles, suggesting that most PMNs may have incorpo-
rated/internalized these terminal complement proteins
from the C5b-9/MAC bound cellular debris because, as
shown in Figure 3, cultured PMNs lack the expression of
terminal complement mRNAs.
In all, quantitative data of infiltrating PMNs associating
with C1q and C3 after SCI support the demonstrated
expression of early complement mRNAs and proteins by
cultured peritoneal PMNs. However, although cultured
peritoneal PMNs lack mRNA expression for terminal com-
plement proteins, infiltrating PMNs were associated with
terminal complement proteins in vivo 3 days post-SCI,
suggesting the internalization of ingested complement by
infiltrating PMNs after injury.
Discussion
Data presented here provide the first characterization of
early and terminal complement proteins associated with
PMNs in vitro and in vivo after traumatic SCI. We have
shown that cultured PMNs expressed mRNAs encoding
for the early proteins C1q, C3, and C4, but not the termi-
nal proteins C5, C6, C7, and C9 in vitro. Complement
association with cultured PMNs was also demonstrated by
immunofluroescence and flow cytometry, confirming
Time course of PMN infiltration after a moderate SCI at T9,  demonstrated by flow cytometry in the injured spinal cord Figure 6
Time course of PMN infiltration after a moderate 
SCI at T9, demonstrated by flow cytometry in the 
injured spinal cord. Cells isolated from spinal cord (T8-
T10) were labeled with a FITC-conjugated anti-PMN anti-
body before analyzed on a FACS Calibur flow cytometer. 
Spinal cord tissues were collected from uninjured control or 
injured animal 30 minutes, 2 hours, 24 hours, 3 days, or 7 
days after SCI. The number of PMNs detected in the injured 
or uninjured spinal cord was visualized by dot plots (A), and 
represented as the percent of cells in the spinal cord relative 
to uninjured control (B). All flow cytometric gates were set 
using control IgG isotype labeled cells. # = significantly (P < 
0.05) different from uninjured control. n = 5. Number of 
experiment replication = 2.Journal of Neuroinflammation 2008, 5:26 http://www.jneuroinflammation.com/content/5/1/26
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that PMNs were associated with the early complement
proteins that included C1q and C3. Additionally, we have
characterized for the first time the localization/association
of complement with the infiltrating PMNs in the injured
spinal cord, demonstrating that the percentage of infiltrat-
ing PMNs that was associated with C1q or C3 in the
injured spinal cord is twice as much as that detected in
culture. More importantly and unlike PMNs in culture,
most of the infiltrating PMNs were also associated with
C7 and C5b-9/MAC in the injured spinal cord, suggesting
that PMNs were incorporating/internalizing terminal
complement proteins and C5b-9/MAC bound debris/
damage cells at the injury microenvironment.
Although our assays did not detect mRNAs encoding for
terminal complement proteins by cultured PMNs in our
culture conditions, previous studies have suggested the
storage and release of several terminal proteins by cul-
tured PMNs in other culture conditions. These studies sug-
gested that cell lysates and supernatant collected from
cultured PMNs that were exposed to cytokines or C. albi-
cans hyphae opsonized with normal human serum had
elevated levels of C6 and C7 proteins [18,19]; however, it
was not conclusive that these proteins were produced by
PMNs in culture because (1) the rise in C6 or C7 in culture
could have been released by C. albicans hyphae or derived
from normal human serum, (2) the inhibition of protein
biosynthesis by cycloheximide did not affect the rise in C6
or C7 in PMN cultures [18], and (3) conclusive evidence
showing that PMNs are actively expressing these terminal
complement mRNAs or proteins has been lacking in the
literature. Our data show that cultured PMNs do not
express mRNAs encoding for terminal complement pro-
teins in vitro, even after exposure to numerous stimulants.
The lack of terminal complement mRNAs in cultured
PMNs may not have been unexpected because several
studies have suggested that C6 and C7 are not actively syn-
thesized by PMNs in culture, but were likely presynthe-
sized in PMNs during differentiation in the bone marrow,
stored in cytoplasmic vesicles, and subsequently released
during circulation [18,34]. Although the concrete evi-
dence of this occurrence has not been previously demon-
strated, the likelihood of this occurrence can potentially
clarify the lack of conclusive evidence showing active
expression/generation of terminal complement mRNAs
and proteins by cultured PMNs.
Contrary to our in vitro data showing the lack of terminal
complement expression by cultured PMNs, our in vivo
data show for the first time that infiltrating PMNs in the
spinal cord 3 days post-SCI were associated with terminal
complement proteins, suggesting that PMNs incorpo-
rated/internalized C5b-9/MAC bound debris. Our data
also suggest the incorporation or internalization of C7 or
C5b-9/MAC bound cellular debris because C7 and C5b-9/
MAC associated with infiltrating PMNs were most likely
localized to granular vesicles within PMNs at the spinal
cord epicenter region. Furthermore, the localization of
most C7 or C5b-9/MAC in the cytoplasm and not on the
surface of PMNs suggests that these terminal complement
proteins were not mediating lysis of PMNs. Moreover,
data suggest that the association/localization of terminal
proteins with infiltrating PMNs was likely attributed to
the elevated internalization of C7 or C5b-9/MAC bound
cellular debris in accordance with a phagocytic role, and
has important implications for a PMN role in the local
complement-mediated events at the injury epicenter
region of the spinal cord. Alternatively, the proinflamma-
tory microenvironment of the injured spinal cord could
have induced a gain of phenotypic expression not
observed in vitro.
Unlike the controversial expression/production of termi-
nal proteins by PMNs, expression/production of C3 by
PMNs has been clearly demonstrated in culture [16,17].
Our data confirm C3 expression by PMNs in culture, and
demonstrate the expression of C1q and C4 by PMNs, pro-
viding a more complete characterization of PMN expres-
sion of the early complement proteins in culture.
Furthermore, we have shown in vivo that most infiltrating
PMNs (over 70%) in the spinal cord epicenter region 3
days post-SCI were associated with the immunolabeling
of C1q or C3, compared to less than 30% of cultured
PMNs in vitro. Our data suggest an increase in comple-
ment association with the infiltrating PMNs after SCI. Our
data also provide important implications for the role of
PMN infiltration was observed at the spinal cord epicenter  region after SCI Figure 7
PMN infiltration was observed at the spinal cord epi-
center region after SCI. Cross sections of rat spinal cord 
adjacent to the epicenter region were immunolabeled for 
PMNs 3 days (A) or 42 days (B) after a moderate contusion 
to the spinal cord (T9).Journal of Neuroinflammation 2008, 5:26 http://www.jneuroinflammation.com/content/5/1/26
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Infiltrating PMNs in the injured spinal cord are associated with the early and terminal complement proteins 3 days post-SCI Figure 8
Infiltrating PMNs in the injured spinal cord are associated with the early and terminal complement proteins 3 
days post-SCI. Cells isolated from spinal cord (T8-T10) of control (A) or injured rats (B & C) were labeled with a FITC-con-
jugated anti-PMN antibody and a Cy5-conjugated antibody for C1q, C3, C7 or C5b-9, or appropriate IgG controls before ana-
lyzed on a FACS Calibur flow cytometer. After 3 days following SCI (B), the number of cells positive for C1q, C3, C7, or C5b-
9 was elevated compared to that from control (A). However, only some of the complement-positive cells were PMNs (C & E) 
and that most PMNs that infiltrated the injured spinal cord were also positive for C1q, C3, C7, and C5b-9 (C & D). All flow 
cytometric gates were set using control IgG isotype labeled cells. # = significantly (P < 0.05) different from uninjured control 
(Con). n = 5. Number of experiment replication = 2.Journal of Neuroinflammation 2008, 5:26 http://www.jneuroinflammation.com/content/5/1/26
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PMN-generated/internalized complement in numerous
complement-mediated events after CNS injury. C1q has
been suggested to affect stem cell migration and fate
[35,36], while C3a and C5a have been suggested to pro-
mote and reduce neurotoxicity [37-40]. Moreover, previ-
ous studies have shown that C1q and C3 have high
affinity for myelin [41-43], and previous work in our lab-
oratory has shown that C1q and factor B co-localize with
axons [5] and degenerating myelin (unpublished data) in
the injured spinal cord. Degenerating myelin has been
thoroughly demonstrated to inhibit axon growth and
regeneration; however, the effect of complement bound
to myelin after CNS injury is not known and has not been
previously investigated. Although it is likely that the bind-
ing of complement opsonizes myelin debris for degrada-
tion, it is feasible that complement bound to myelin
affects myelin inhibition of axon growth and regenera-
tion. Moreover, glial cells of the CNS are known to express
receptors for C3a and C5a, and therefore are likely to take
part in the complement-mediated events following CNS
injury [37,44]. The binding of C3a or C5a to receptors on
oligodendrocytes and astrocytes may affect demyelination
and scar formation following CNS injury, because (1)
activation of C5aR by C5a peptide fragments has shown
to trigger apoptosis in cortical and hippocampal cultures
[40]; and (2) activation of C3a and C5a receptors on
astrocytes has been suggested to regulating scar formation
and glial cell activation/chemotaxis [45,46].
As the first predominant immune cells to infiltrate the
CNS after injury, PMNs may significantly elevate the level
of complement proteins/activation in the injured spinal
cord. Previous studies have shown that the expression or
display of complement proteins is prominantly detected
in the CNS 24 hours after TBI [47,48] and SCI [5,49]. Co-
incidentally, time course data of PMN infiltration in pre-
vious studies suggested that PMN numbers in the injured
spinal cord also peaked 24 hours post-injury [50,51];
however, the localization/association of complement
with the infiltrating PMNs in the injured spinal cord has
not been previously characterized. Data in the present
study confirm the peak of PMN infiltration 24 hours post-
SCI and characterize for the first time, the association of
complement with the infiltrating PMNs in the injured spi-
nal cord, suggesting that PMNs may be an important con-
tributor to this complement surge shortly post-SCI.
However, other cells in the CNS (eg. astrocytes and neu-
rons) have been shown to express/generate numerous
complement proteins and may also contribute to this
early complement surge after SCI [8,52,53]. CNS cells
expressing complement proteins after SCI are widely dis-
tributed along the spinal cord outside of the injury epi-
center, and a previous study has detected a surge of
complement proteins/activation in the injured spinal
cord as far as 20 mm rostral to injury epicenter [5]. In con-
trast, PMNs infiltrating the rodent spinal cord after injury
are generally localized proximal to the epicenter, and nei-
ther we nor others have observed PMNs at large distances
distal to this region.
The expression of early complement proteins by PMNs
suggests that PMN-derived complement proteins may
affect inflammation and other suggested alternative roles
for complement. Animals that are deficient in C3 or
received neutralizing antibodies or receptors for C1q or
C3 have been shown to have less inflammation after CNS
injury/disease, suggesting an important role for comple-
ment in recruiting inflammatory cells to sites of injury
[54-56]. As suggested in the present study, complement
delivered/internalized by PMNs at the injury site may
affect the recruitment of macrophages and lymphocytes
that infiltrating the injured CNS a few days later. Macro-
phages and T-cells have been suggested to affect both
injury and regeneration after SCI and TBI [57-59]; there-
fore, the mediation of inflammation by PMN-delivered/
internalized complement may have critical outcome to
CNS injury and recovery. An alternative role for PMN-
derived complement proteins could also affect neurogen-
esis and migration of neural progenitor cells (NPCs) in
the injured CNS. A previous study has shown that NPCs
PMNs are associated with C7 (A) and C5b-9 (B) at the injury  epicenter region 3 days post-SCI Figure 9
PMNs are associated with C7 (A) and C5b-9 (B) at 
the injury epicenter region 3 days post-SCI. Cross sec-
tions of rat spinal cord epicenter region were immunolabeled 
for PMNs (green) and C7 (red) or C5b-9 (red) 3 days after a 
moderate contusion injury to the spinal cord (T9). Lower 
panels are higher magnifications of selected areas taken from 
upper panels.Journal of Neuroinflammation 2008, 5:26 http://www.jneuroinflammation.com/content/5/1/26
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express receptors for complement anaphylatoxins C3a
and C5a, and has suggested that complement promotes
neurogenesis because C3 (-/-) deficient mice and mice
lacking C3aR or mice treated with a C3aR antagonist had
impaired ischemia-induced neurogenesis [60]. As demon-
strated in previous studies that showed PMNs synthesis
and release of C3 in culture [16,17], and in the present
study that showed PMNs express high levels of C3 mRNAs
and proteins in vitro and in the injured spinal cord, it is
likely that PMNs may contribute to the elevated level of
complement involved in post-injury neurogenesis. Fur-
thermore, the complement anaphylatoxins C3a and C5a
are potent chemoattractants that could guide NPCs
toward the site of injury; thus, the expression of C3a and
C5a receptors by NPCs suggests the feasibility that com-
plement may also affect NPC migration in the injured
CNS. Critically, PMNs are mostly concentrated at the
lesion site after SCI, and are expected to generate a few
complement and derived fragments that may guide and
direct NPC migration toward the site of injury.
Conclusion
Although proteins of the complement system that are
involved in complement activation and numerous other
functions are thought to originate mostly from the liver,
our data provide novel insight into an important cellular
source of complement at the local microenvironment
post-SCI. More importantly, the early presence of PMNs
after injury and the long-term infiltration of PMNs at the
injury epicenter for many months after SCI suggest that
PMNs are likely to affect complement function and activa-
tion in the local SCI microenvironment.
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